Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Income from Continuing Operations (2018 - 2025)

10x Genomics (TXG) has disclosed Income from Continuing Operations for 8 consecutive years, with 16252000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 66.85% to 16252000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 43544000.0 through Dec 2025, up 76.16% year-over-year, with the annual reading at 43544000.0 for FY2025, 76.16% up from the prior year.
  • Income from Continuing Operations hit 16252000.0 in Q4 2025 for 10x Genomics, up from 27472000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 34538000.0 in Q2 2025 to a low of 92986000.0 in Q3 2023.
  • Historically, Income from Continuing Operations has averaged 35274650.0 across 5 years, with a median of 36825000.0 in 2024.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 483.22% in 2022 and later skyrocketed 191.14% in 2025.
  • Year by year, Income from Continuing Operations stood at 18449000.0 in 2021, then rose by 6.69% to 17215000.0 in 2022, then tumbled by 184.36% to 48952000.0 in 2023, then fell by 0.16% to 49028000.0 in 2024, then skyrocketed by 66.85% to 16252000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for TXG at 16252000.0 in Q4 2025, 27472000.0 in Q3 2025, and 34538000.0 in Q2 2025.